• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Regeneron boosts profits, misses revenue in Q3

November 4, 2016 By Sarah Faulkner

Regeneron boosts profits, misses revenue in Q3Shares in Regeneron (NSDQ:REGN) gained today after the biopharmaceutical company crushed earnings expectations on Wall Street with its 3rd-quarter results.

The Tarrytown, N.Y.-based company posted profits of $264.8 million, or $2.27 per share, on sales of $1.22 billion for the 3 months ended Sept. 30, for bottom-line growth of 26% on sales growth of 7.3% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $3.13, ahead of the consensus on The Street, where analysts were looking for sales of $1.29 billion.

“In the 3rd quarter, we saw continued U.S. sales growth with Eylea in retinal diseases and with Praluent in hypercholesterolemia,” president & CEO Dr. Leonard Schleifer said in prepared remarks. “We are preparing for a potential approval and launch for Dupixent in atopic dermatitis and continuing to advance our pipeline at all stages.”

Regeneron bumped up its full year sales growth forecast for Eylea from 20-25% to 23-25%.

REGN shares were trading at $343.37 apiece today in afternoon trading, up +2.57%.

Filed Under: Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Regeneron

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS